Skip to main content
. 2020 Nov 18;11:5872. doi: 10.1038/s41467-020-19760-3

Fig. 6. Overexpression of myeloid KLF2 protects against metabolic disease.

Fig. 6

a Myeloid KLF2 overexpressing mice (K2Tg) are protected against HFD-induced weight gain, n = 15, p = 0.0253 (2 weeks), 0.00238 (4 weeks), 0.005 (8 weeks). b K2Tg mice consume similar amounts of food daily compared to LysM mice across a HFD regimen, LysM n = 11, K2Tg n = 9. c K2Tg have diminished plasma leptin levels after HFD, LysM n = 5, K2Tg n = 4. d Western blot on hypothalamic lysates from HFD-fed mice demonstrate decreased interleukin-1 beta (IL-1β) production in K2Tg mice, LysM n = 5, K2Tg n = 4. e K2Tg have decreased inflammatory gene expression in WAT after HFD, n = 4, p values: Tnfa = 0.0046, Ccl2 = 0.00019, Cd64 = 0.0168. f K2Tg have decreased inflammatory gene expression in liver after HFD, n = 4, p values: Il1b = 0.0099, Ccl2 = 0.0394, Cd64 = 0.0155. g IPGTT and h IPITT demonstrating improved glucose handling by K2Tg after HFD, LysM n = 4, K2Tg n = 5. i Working model describing how myeloid KLF2 expression affects metabolic disease centrally and peripherally. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired two-tailed Student’s t-test. Error bars represent SEM. All mice on were fed HFD for 1 month unless otherwise indicated. n represents biologically independent mice throughout entire figure. Source data are provided as a Source Data file.